TBK1 and non-small cell lung carcinoma: We conducted a multisite, phase 1b, open-label study of the first-generation EGFR TKI erlotinib in combination with JAK1/2 and TBK1 inhibitor momelotinib in 11 patients with EGFR TKI-treatment–naive EGFR-mutated advanced NSCLC.